JP2023534812A - 損傷した腎臓に薬物送達するためのデンドリマー組成物および方法 - Google Patents

損傷した腎臓に薬物送達するためのデンドリマー組成物および方法 Download PDF

Info

Publication number
JP2023534812A
JP2023534812A JP2023503110A JP2023503110A JP2023534812A JP 2023534812 A JP2023534812 A JP 2023534812A JP 2023503110 A JP2023503110 A JP 2023503110A JP 2023503110 A JP2023503110 A JP 2023503110A JP 2023534812 A JP2023534812 A JP 2023534812A
Authority
JP
Japan
Prior art keywords
dendrimer
composition
ppar
agents
renal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023503110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534812A5 (enExample
Inventor
ジェフリー エル． クリーランド，
カナン ランガラマヌジャム，
スジャータ カナン，
リシ シャルマ，
ラ ローザ， サンティアゴ アピアニ
Original Assignee
アシュバッタ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アシュバッタ セラピューティクス， インコーポレイテッド filed Critical アシュバッタ セラピューティクス， インコーポレイテッド
Publication of JP2023534812A publication Critical patent/JP2023534812A/ja
Publication of JP2023534812A5 publication Critical patent/JP2023534812A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023503110A 2020-07-17 2021-07-16 損傷した腎臓に薬物送達するためのデンドリマー組成物および方法 Pending JP2023534812A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063053228P 2020-07-17 2020-07-17
US63/053,228 2020-07-17
PCT/US2021/042097 WO2022016120A1 (en) 2020-07-17 2021-07-16 Dendrimer compositions and methods for drug delivery to injured kidney

Publications (2)

Publication Number Publication Date
JP2023534812A true JP2023534812A (ja) 2023-08-14
JP2023534812A5 JP2023534812A5 (enExample) 2024-07-24

Family

ID=79555049

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023503110A Pending JP2023534812A (ja) 2020-07-17 2021-07-16 損傷した腎臓に薬物送達するためのデンドリマー組成物および方法

Country Status (9)

Country Link
US (1) US20230364244A1 (enExample)
EP (1) EP4181913A4 (enExample)
JP (1) JP2023534812A (enExample)
CN (1) CN116249558A (enExample)
AU (1) AU2021310470A1 (enExample)
CA (1) CA3189682A1 (enExample)
IL (1) IL299891A (enExample)
PH (1) PH12023550133A1 (enExample)
WO (1) WO2022016120A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022552818A1 (en) 2020-04-24 2024-03-25 Ashvattha Therapeutics Inc Dendrimer compositions and methods for treatment of severe acute respiratory distress syndrome
EP4237009A4 (en) * 2020-10-30 2025-09-24 Ashvattha Therapeutics Inc Radiolabeled ether dendrimer conjugates for PET imaging and radiotherapy
US20250333732A1 (en) * 2022-05-23 2025-10-30 Empirico Inc. Treatment of sos2 related diseases and disorders
WO2025137151A2 (en) * 2023-12-18 2025-06-26 The Johns Hopkins University Dendrimer compositions for the treatment of atherosclerosis, obesity, and metabolic syndromes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012116753A (ja) * 2009-03-26 2012-06-21 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤活性化受容体の活性化剤
WO2011053618A2 (en) * 2009-10-30 2011-05-05 The Regents Of The University Of Michigan Hydroxyl-terminated dendrimers
WO2016025741A1 (en) * 2014-08-13 2016-02-18 The Johns Hopkins University Selective dendrimer delivery to brain tumors
CN105879055A (zh) * 2014-11-11 2016-08-24 董勤 载cxcr4小分子rna聚酰胺树枝状聚合物纳米微粒
JP7108306B2 (ja) * 2015-10-29 2022-07-28 ザ・ジョンズ・ホプキンス・ユニバーシティー デンドリマー組成物ならびに壊死性腸炎および他の胃腸障害の処置における使用
JP7088473B2 (ja) * 2015-10-29 2022-06-21 ザ・ジョンズ・ホプキンス・ユニバーシティー ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法
US11771702B2 (en) * 2018-11-30 2023-10-03 Amiram Goldblum Agonists of PPAR-δ
AU2020397063A1 (en) * 2019-12-04 2022-07-07 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery
AU2020397064A1 (en) * 2019-12-04 2022-07-07 Ashvattha Therapeutics, Inc. Triantennary N-Acetylgalactosamine modified hydroxyl polyamidoamine dendrimers and methods of use thereof

Also Published As

Publication number Publication date
EP4181913A4 (en) 2025-02-19
US20230364244A1 (en) 2023-11-16
CA3189682A1 (en) 2022-01-20
CN116249558A (zh) 2023-06-09
AU2021310470A1 (en) 2023-03-02
EP4181913A1 (en) 2023-05-24
PH12023550133A1 (en) 2024-06-24
IL299891A (en) 2023-03-01
WO2022016120A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
US10172962B2 (en) Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases
US20230364244A1 (en) Dendrimer compositions and methods for drug delivery to injured kidney
JP6342575B2 (ja) 脳腫瘍への選択的デンドリマー送達
EP3368028B1 (en) Denderimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders
WO2019141264A1 (zh) 用于靶向活化cd44分子的树枝状聚合物纳米载体递送系统、其制备方法和用途
CN115103690B (zh) 用于将药物递送至眼的树枝状大分子组合物和方法
JP2017529325A (ja) 神経障害およびｃｎｓ障害の処置におけるデンドリマー組成物および使用
US20250009894A1 (en) Dendrimer compositions and methods for treatment of severe acute respiratory distress syndrome
Magruder et al. Selective localization of a novel dendrimer nanoparticle in myocardial ischemia-reperfusion injury
HK40093382A (zh) 用於将药物递送至受伤肾脏的树枝状大分子组合物和方法
US20250352653A1 (en) Neuron targeted 2-deoxyglucose dendrimer for imaging and treatment of neurological diseases
US20230338554A1 (en) Galactosylated dendrimers for targeted intracellular delivery to hepatocytes
HK40093332A (zh) 用於治疗重度急性呼吸窘迫综合症的树枝状大分子组合物和方法
HK40119489A (zh) 用於靶向递送治疗剂至神经元的树枝状聚合物组合物
Qin et al. Precision Medicine for Rheumatoid Arthritis: Chondroitin Sulfate-Based Nanoparticles for Targeted Therapeutics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260205